The estimated Net Worth of Daniel Lochner is at least $2.43 Millón dollars as of 1 November 2021. Mr. Lochner owns over 8,590 units of Oyster Point Pharma Inc stock worth over $650,329 and over the last 5 years he sold OYST stock worth over $0. In addition, he makes $1,780,530 as Chief Financial Officer at Oyster Point Pharma Inc.
Daniel has made over 7 trades of the Oyster Point Pharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 8,590 units of OYST stock worth $98,871 on 1 November 2021.
The largest trade he's ever made was exercising 9,109 units of Oyster Point Pharma Inc stock on 24 February 2021 worth over $104,845. On average, Daniel trades about 3,357 units every 52 days since 2019. As of 1 November 2021 he still owns at least 58,221 units of Oyster Point Pharma Inc stock.
You can see the complete history of Mr. Lochner stock trades at the bottom of the page.
Daniel J. Lochner serves as Chief Financial Officer of the Company. Previously, Mr. Lochner was a Managing Director within the Investment Management Division of Goldman Sachs where he served as a lead equity portfolio manager and healthcare investor for various fund strategies. Mr. Lochner joined the Investment Management Division of Goldman Sachs in 2005 as an equity investor, a position he maintained during his tenure at the firm. Mr. Lochner received a B.A. in Economics from the University of Richmond and an Executive M.B.A. from Columbia University.
As the Chief Financial Officer of Oyster Point Pharma Inc, the total compensation of Daniel Lochner at Oyster Point Pharma Inc is $1,780,530. There are 2 executives at Oyster Point Pharma Inc getting paid more, with Jeffrey Nau having the highest compensation of $4,037,700.
Daniel's mailing address filed with the SEC is C/O OYSTER POINT PHARMA, INC., 202 CARNEGIE CENTER, SUITE 106, PRINCETON, NJ, 08540.
Over the last 5 years, insiders at Oyster Point Pharma Inc have traded over $24,486,000 worth of Oyster Point Pharma Inc stock and bought 3,552,871 units worth $59,028,668 . The most active insiders traders include Ali Behbahani, Venture Capital Vi, L.P.Ver... y Clare Ozawa. On average, Oyster Point Pharma Inc executives and independent directors trade stock every 27 days with the average trade being worth of $2,204,444. The most recent stock trade was executed by Daniel Lochner on 1 November 2021, trading 8,590 units of OYST stock currently worth $98,871.
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma's lead product candidate, OC-01 (varenicline) nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. In pre-clinical and clinical studies, OC-01 (varenicline) nasal spray was shown to have a novel mechanism of action via activation of the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit.
Oyster Point Pharma Inc executives and other stock owners filed with the SEC include: